MicroRNA (miRNA)-mediated gene silencing at the translational level has led to novel discoveries for numerous biological processes. Recently, there has been increasing evidence to indicate that miRNAs are involved in normal immune functions and inflammation. In this review, we focus on recent advances that have elucidated the role of miRNAs in B-cell development, differentiation, apoptosis and function. While the regulatory mechanisms of miRNAs in controlling and maintaining B-cell fate remain largely uncharacterized, further studies on miRNAs and their targets will increase our understanding of B-cell development and function. Such studies may be able to provide new therapeutic strategies for treating autoimmune diseases.
INTRODUCTION
MicroRNAs (miRNAs) are an evolutionarily conserved class of approximately 22-nucleotide noncoding RNAs that silence the expression of protein-coding genes by binding to their cognate mRNAs, thus leading to their degradation or translational repression. 1 miRNAs were first discovered in Caenorhabditis elegans, and hundreds of miRNAs have since been identified in mammals. 2 A large portion of the human genome is regulated by miRNAs, and miRNAs play key regulatory roles in almost every physiological process, including development and differentiation. 3 The importance of miRNAs has been increasingly recognized over the past decade, as significant advances have been made in the discovery of novel targets for many cellular functions, including maintenance, differentiation, metabolism and the cell cycle.
Upon rearrangement of the B-cell immunoglobulin heavy and light chain loci, B-cell development follows an ordered series of steps in the bone marrow that involves three defined differentiation stages. The first stage is the pro-B cell, in which the B cells rearrange the immunoglobulin H. This is followed by the pre-B cell, in which the immunoglobulin light chain is rearranged, and the final stage is the immature B cell, which expresses variable amounts of immunoglobulin M. 4 Upon completion of the developmental process, newly formed B cells are disseminated into the peripheral lymphoid organs via the blood stream. B cells are important participants in normal immune responses and autoimmune diseases. Recent studies have demonstrated that miRNA-mediated gene regulation is critical for B-cell differentiation, activation and autoimmune responses. In this review, we provide an overview of the roles of different miRNAs or miRNA clusters in regulating B-cell development and function (Table 1) .
miRNAs in B-cell development and differentiation B-cell development involves a complex sequence of molecular events in either the bone marrow or the peripheral lymphoid organs. The miRNA field is rapidly evolving, and the key role of miRNAs in development and differentiation has become increasingly recognized. miRNAs are first transcribed by RNA polymerase II as primary transcripts (pri-miRNA) and are then processed into mature miRNAs by the type-III RNase endonucleases Drosha and Dicer. 3 The ablation of Dicer aborts the generation of most mature miRNAs. A previous study by Koralov et al. demonstrated that the ablation of Dicer blocked the differentiation of pro-B cells to pre-B cells and significantly affected antibody diversity by increasing the diversification of Igk variable regions and changing D H element usage of IgH variable regions. Subsequently, Xu et al. 6 investigated the function of Dicer in regulating B-cell terminal differentiation by a specific deletion of Dicer in murine antigen-activated B cells. Interestingly, after immunization with antigen, these mice were unable to produce high-affinity class-switched antibodies, memory B cells and long-lived plasma cells. Moreover, Dicerdeficient germinal center (GC) B cells were found to overexpress cell cycle inhibitor genes and the proapoptotic protein Bim. These results suggest that miRNAs play a crucial role in the regulation of GC B-cell terminal differentiation.
To date, several miRNAs, such as miR-181, miR-150, the miR-17,92 cluster and miR-34a, have been identified as antigenindependent modalities that contribute to B-cell development in the bone marrow. miR-181a. miR-181a was first identified as a regulator of immune cell development. A study by Chen et al.
7 analyzed the expression of approximately 100 cloned miRNAs from the bone marrow, among which miR-181 was found to be highly expressed in the thymus, bone marrow and spleen. Moreover, ectopic expression of miR-181a in hematopoietic stem/progenitor cells induced an increased fraction of B-lineage cells in vitro and in vivo, suggesting that miR-181a positively regulated B-cell differentiation. 7 Recently, Li et al. 8 identified the RNA-binding protein Lin28 as the direct target of miR-181a. It has been shown that miR-181a expression mediates cell differentiation by effectively suppressing Lin28, thus blocking the Lin28-let-7 reciprocal regulatory loop. Ultimately, this promotes megakaryocytic differentiation by upregulating let-7 miRNAs. Since different miRNA expression profiles are found in different cell subsets or tissues, it is currently unclear whether Lin28 is the real target of miR-181a in B cells. miR-150. In 2005, Monticelli et al. 9 first showed that miR-150 was induced during B-cell and T-cell maturation. miR-150 was also predominantly expressed in mature and resting B cells and T cells but not in the progenitors. Subsequently, the authors identified the transcription factor c-Myb as the target of miR-150, which directs multiple steps of B-cell development and is also necessary for the generation of B1 cells. 10 Interestingly, ectopic in vivo expression of miR-150 led to the downregulation of c-Myb in B-cell progenitors. This caused a partial block in B-cell development, thus resulting in severely reduced numbers of mature B-cell subsets and B1 cells. 10 Notably, miR-150-deficient mice displayed an enhanced humoral immune response mediated by T cells, follicular B cells and marginal zone B cells, which resulted in a fourfold expansion of B1 cells. 10 A parallel study by Zhou et al. 11 reported that the overexpression of miR-150 in hematopoietic progenitor/stem cells blocked B-cell development at the pro-to pre-B cell transition. Taken together, these findings highlight the key role of miR-150 in B-cell development.
miR-17,92 cluster. In the human genome, the miR-17,92 cluster encodes six miRNAs, including miR-17, miR-18a, miR-19a, miR-19b, miR-20a and miR-92a, which are all processed from the same precursor transcript. The miR-17,92 cluster is overexpressed in progenitor B cells, and its expression diminishes as the B cells mature. 12 An earlier study showed that a Dicer deletion at the early B cell stage caused an almost complete block at the pro-to pre-B cell transition, which coincided with a clear increase in the pro-apoptotic protein Bim. 5 Consequently, Ventura et al. 12 revealed that the absence of miR-17,92 led to the overexpression of Bim and impaired B-cell development at the pro-B to pre-B cell transition. Moreover, Bim expression was shown to be suppressed in mice that were transgenic for miR-17,92 13 Collectively, these studies indicate that miR-17,92 is pivotal in early B-cell development due to its suppression of Bim. miR-34a. Recent studies have revealed that miR-34a is upregulated in progenitor cells.
14 B cells from mice that constitutively express miR-34a displayed a blockage at the pro-B cell to pre-B cell transition, and mature B cells in these mice were 
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reduced. 4 In this study, the transcription factor Foxp1 was identified as a direct target of miR-34a, and the B-cell block was primarily mediated by Foxp1 suppression. Importantly, the deletion of Foxp1 recapitulated the phenotype of B-cell development induced by miR-34a overexpression. 4 These findings indicate the significant role of miR-34a in B-cell development.
miRNAs in B-cell function and apoptosis miR-155 is required for normal B-cell function and GC responses. Studies have shown that miR-155 is expressed by immune cells and acts as a regulator of innate immune responses. 15 Contained within the noncoding B-cell integration cluster gene, miR-155 is highly expressed in human B-cell lymphomas. [16] [17] [18] [19] [20] [21] In humans, Bic/miR-155 expression has been detected in activated mature B and T lymphocytes, especially GC B cells. 17 Previous studies have explored the regulatory functions of miR-155 by generating knockout mouse models. 22 Rodriguez et al. 22 generated Bic/ miR-155-deficient mice and measured their B-and T-cell responses in vivo after immunization with antigen. These mice failed to express immunoglobulin M, and the antigen-specific antibodies were unable to class switch, indicating an impaired B-cell response. Moreover, after immunization with a live attenuated form of the enteric pathogen Salmonella typhimurinum, Bic/miR-155-deficient mice were more susceptible to disease and succumbed to challenge with the virulent strain. These results demonstrate that miR-155 is necessary for an effective adaptive immune response.
A parallel study by Thai et al. 23 demonstrated that the spleens of miR-155-deficient mice had markedly fewer GCs following an antigenic challenge in comparison to their wild-type littermate controls. Conversely, more and larger GCs and an increased number of class-switched antibodies were observed in mice ectopically expressing miR-155. Furthermore, the authors also observed a reduced production of tumor-necrosis factor-a and lymphotoxin-a by miR-155-deficient B cells after in vitro and in vivo activation, suggesting that miR-155 controls GC responses at the level of cytokine production. 23 Therefore, one possible molecular mechanism of miR-155 in B cells may be to target the E-twenty-six-family transcription factor PU.1, which is a crucial regulator of early B-cell commitment and development. The suppression of PU.1 by miR-155 could explain the observed phenotype of B-cell defects. [24] [25] [26] In addition, activation-induced cytidine deaminase (AID) is recognized as another important target of miR-155, and disrupting the miR-155-mediated suppression of AID might lead to increased class switching. 27 Overall, the above results indicate a key role for miR-155 in lymphocyte development, which supports the notion that a single miRNA can exert critical control on the lymphocyte differentiation process.
miR-181b negatively regulates the class-switch recombination (CSR) reaction. It is well recognized that activated B cells reshape their primary antibody repertoire upon an antigen encounter via AID-initiated somatic hypermutation and CSR events. 28 Recently, the miRNA profile involved in the regulation of CSR was screened, and miR-181b was identified as the regulator of CSR in activated B cells. miR-181b is known to directly target AID and downregulate its expression, resulting in impaired CSR. 28 These results reveal a novel regulatory mechanism for the restriction of AID activity, and they provide new insight into the understanding of B-cell malignant transformation.
miRNAs regulate B-cell apoptosis. Certain miRNAs have been identified as regulators of B-cell apoptosis. For example, miR15a and miR-16-1 regulate several mRNAs that are involved in apoptosis or cell cycle progression. 29 It remains to be investigated whether miRNAs are involved in modulating B-cell apoptosis. To date, it has been shown that miR-125b is overexpressed in acute myeloid leukemia and myelodysplastic syndrome patients. miR-125b expression was shown to enhance the proliferation of murine pre-B1 cells by targeting the B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a, an activator of immunoglobulin heavychain transcription. Moreover, the overexpression of miR125b was found to protect pre-B1 and leukemic B-cell lines from apoptosis by blocking caspase activation independently of p53 and BAK1. 30 In addition, B-cell receptor (BCR) signaling-induced apoptosis prevented the outgrowth of autoreactive B cells, which is critical for B cell-mediated tolerance. The ectopic expression of miR-150, miR-181a1b1 and the miR-17,92 cluster has been shown to sensitize WEHI-231 cells to apoptosis induced by BCR stimulation. 31 The expression of proteins involved in apoptosis may be regulated by these miRNAs. For example, the antiapoptotic genes Bcl-2 and Mcl-1 have been identified as targets of miR-181. [32] [33] [34] Since the dysregulation of BCR signaling may contribute to autoimmune diseases and lymphomagenesis, 31 these miRNAs may serve as potential biomarkers for the diagnosis and prognosis of autoimmune diseases or other disorders.
Role of miRNAs in autoimmune disease. In addition to their key roles in the regulation of immune cell development and the immune response, miRNAs have been increasingly recognized for their contributions to autoimmunity. Due to their primary role in the secretion of autoantibodies, B cells are closely tied to the pathophysiology of many autoimmune diseases. Previous studies have demonstrated that Dicer-deficient B cells exhibit a skewed BCR repertoire with the hallmarks of autoreactivity. Furthermore, the titers of anti-dsDNA, anti-ssDNA and anticardiolipin autoantibodies were substantially increased in the sera from these mice. Prominent immunoglobulin G deposition, lymphocyte infiltration and glomerulus damage have also been observed in the kidneys of these mice. 35 Taken together, these results confirm that miRNAs regulate B-cell function and contribute to autoimmunity.
Several studies have reported altered miRNA expression profiles in autoimmune diseases, specifically in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). miR-21 expression has been shown to be upregulated in lupus B and T cells of B6.Sle123 mice, a spontaneous mouse model of SLE.
Interestingly, silencing of miR-21 in vivo reversed the splenomegaly observed in these mice. Furthermore, PDCD4, which regulates cell differentiation, cell cycle and apoptosis, has been identified as the direct target of miR-21. However, a role for PDCD4 in SLE models and SLE patients has not yet been elucidated. 36 A recent study examined the miRNA expression patterns of splenic lymphocytes taken from three murine lupus models (MRL-lpr, B6-lpr and NZB/W F1 ) The authors observed that the expression profile of dysregulated miRNAs (miR-182-96-183 cluster, miR-31 and miR-155), as well as the expression of miR-150, miR-127 and miR-379, was greatly upregulated in both purified splenic B and T cells from MRL-lpr mice. 37 Another recent study identified a significant correlation between autoantibody production and miR-15a levels in a B/ W mouse model. Notably, miR-15a was highly expressed in the immunosuppressive B-cell subset (B-10). 38 These results suggest that miR-15a induced a loss of regulatory B cells by targeting the antiapoptotic protein Bcl-2, which in turn led to enhanced autoantibody production by autoreactive B cells. 38 The most common genomic aberration in B-cell chronic lymphocytic leukemia is the deletion of the human chromosomal region 13q14, corresponding to the mouse chromosomal region 14qC3, which harbors the miR-15a/miR-16-1 cluster. In a recent in vivo mouse study, the loss of the miR-15a/16-1 cluster was shown to accelerate the proliferation of B lymphocytes, resulting in a B-cell autonomous lymphoproliferative disorder. 39 These findings reveal elevated levels of miR-15a in the development of autoimmune disease and further highlight the significant contribution of miR-15a in autoimmune disease pathogenesis.
Recent studies on synovial tissue from RA patients revealed that miR-146a could be detected in CD79a 1 B cells by in situ hybridization. 40 Furthermore, miR-146a expression was markedly upregulated on T cells, synoviocytes and macrophages of RA patients. Although many studies, including our recent findings, have suggested a role for miR-146a in cell apoptosis and cytokine secretion, neither its expression nor its functional role in B cells has been clearly determined. 41 miR-146a has multiple targets, including IRAK1, IRAK2, TRAF6, IRF-5, FAS and FADD, which indicates the complex function of miR-146a in autoimmunity. 42 To date, several studies have indicated a possible role for miRNAs in the regulation of autoimmune diseases. Further studies on the altered expression of miRNAs that influence specific pathways, and thereby affect autoimmune disease phenotypes, may help in the exploration and validation of new therapeutic options for autoimmune diseases.
CONCLUDING REMARKS
It is clear that miRNAs are emerging as important regulators in immune functions and autoimmune diseases, but the specific roles of miRNAs in the regulation/dysregulation of B cell are still being unraveled (Figure 1 ). Despite significant advances in our understanding of the miRNA-dependent regulation of Bcell development and function, many questions remain unanswered. First, although many studies have focused on the regulatory functions of miRNAs, the mechanisms by which miRNAs silence their target mRNAs have not been fully elucidated. Each miRNA is predicted to target and regulate a multitude of different mRNA transcripts, thus influencing many biological processes, but very few miRNA targets have been experimentally validated. This necessitates further identification of the most likely targets of miRNAs, either within particular B-cell subsets or at specific developmental stages. Since most miRNAs regulate cellular functions through complex mechanisms involving precise, spatio-temporal control of gene expression in association with many other miRNAs, extensive studies are needed to understand the networks controlled by miRNAs in B cells. Second, although some miRNAs appear to be altered in autoimmune disease animal models, the detailed roles of these miRNAs in human diseases have not yet been characterized. Therefore, little evidence exists to validate miRNAs as novel candidate biomarkers for the diagnosis and therapy of human diseases. Further studies on the crucial roles of miRNAs in regulating B-cell development and function within this complex molecular network will not only increase our understanding of immune homeostasis, but will elucidate novel molecular pathways involved in autoimmunity. Such discoveries may ultimately lead to the identification of new therapeutic targets for the treatment of human autoimmune diseases.
